Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry.
